Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Philip L. Mccarthy

Hematology Oncology | Transplant Surgery
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
Offers Telehealth
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Philip Mccarthy is a Hematologist Oncology specialist and a Transplant Surgeon in Buffalo, New York. Dr. Mccarthy is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 190 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

ROSWELL PARK CANCER INSTITUTE
Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Lenalidomide, Melphalan
Study Phase: Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Biological
Study Drugs: TAK-007, Chemotherapy Agents
Study Phase: Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss
A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss
Enrollment Status: Completed
Publish Date: March 13, 2024
Intervention Type: Biological
Study Drug: Denosumab
Study Phase: Phase 2
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: January 31, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

190 Total Publications

ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device.
ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device.
Journal: Bone marrow transplantation
Published: May 19, 2025
Similar Doctors
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Robert M. Zielinski
Hematology Oncology | Hematology | Oncology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Robert M. Zielinski
Hematology Oncology | Hematology | Oncology

Buffalo Medical Group, P.C.

85 High St, 
Buffalo, NY 
 (1.4 miles away)
716-630-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Zielinski is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Zielinski is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Intestinal Leiomyoma, Felty Syndrome, Primary Mediastinal B-Cell Lymphoma (PMBCL), and Hemangiopericytoma.

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Parikshit Padhi
Hematology Oncology | Hematology | Oncology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Parikshit Padhi
Hematology Oncology | Hematology | Oncology

General Physician PC

45 Spindrift Dr, Suite 100, 
Williamsville, NY 
 (8.2 miles away)
716-422-5422
Languages Spoken:
English
See accepted insurances

Parikshit Padhi is a Hematologist Oncology specialist and a Hematologist in Williamsville, New York. Dr. Padhi is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Paget Disease of the Breast, Primary Mediastinal B-Cell Lymphoma (PMBCL), Breast Cancer, and Lung Cancer.

Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Yijun Cheng
Hematology Oncology | Oncology | Hematology
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Yijun Cheng
Hematology Oncology | Oncology | Hematology

Buffalo Medical Group, P.C.

85 High St, 
Buffalo, NY 
 (1.4 miles away)
716-630-1000
Languages Spoken:
English
See accepted insurances

Yijun Cheng is a Hematologist Oncology specialist and an Oncologist in Buffalo, New York. Dr. Cheng is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Autoimmune Hemolytic Anemia, Thrombocytopenia, Multiple Myeloma, and Iron Deficiency Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccarthy's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 12 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile